228 related articles for article (PubMed ID: 29455292)
1. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.
Maggio SE; Saunders MA; Baxter TA; Nixon K; Prendergast MA; Zheng G; Crooks P; Dwoskin LP; Slack RD; Newman AH; Bell RL; Bardo MT
Psychopharmacology (Berl); 2018 May; 235(5):1439-1453. PubMed ID: 29455292
[TBL] [Abstract][Full Text] [Related]
2. An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.
Maggio SE; Saunders MA; Nixon K; Prendergast MA; Zheng G; Crooks PA; Dwoskin LP; Bell RL; Bardo MT
Drug Alcohol Depend; 2018 Dec; 193():154-161. PubMed ID: 30384323
[TBL] [Abstract][Full Text] [Related]
3. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
4. Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats.
Chandler CM; Maggio SE; Peng H; Nixon K; Bardo MT
Drug Alcohol Depend; 2020 Jul; 212():107988. PubMed ID: 32387915
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.
Waeiss RA; Knight CP; Hauser SR; Pratt LA; McBride WJ; Rodd ZA
Psychopharmacology (Berl); 2019 Jun; 236(6):1887-1900. PubMed ID: 30758525
[TBL] [Abstract][Full Text] [Related]
6. bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
Wooters TE; Smith AM; Pivavarchyk M; Siripurapu KB; McIntosh JM; Zhang Z; Crooks PA; Bardo MT; Dwoskin LP
Br J Pharmacol; 2011 May; 163(2):346-57. PubMed ID: 21232049
[TBL] [Abstract][Full Text] [Related]
7. Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats.
Scuppa G; Cippitelli A; Toll L; Ciccocioppo R; Ubaldi M
Drug Alcohol Depend; 2015 Nov; 156():126-132. PubMed ID: 26383997
[TBL] [Abstract][Full Text] [Related]
8. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice.
Kamens HM; Andersen J; Picciotto MR
Psychopharmacology (Berl); 2010 Mar; 208(4):613-26. PubMed ID: 20072781
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Long-Term Varenicline Administration on Ethanol and Sucrose Seeking and Self-Administration in Male P Rats.
Czachowski CL; Froehlich JC; DeLory M
Alcohol Clin Exp Res; 2018 Feb; 42(2):453-460. PubMed ID: 29168193
[TBL] [Abstract][Full Text] [Related]
10. The Nicotinic α6-Subunit Selective Antagonist bPiDI Reduces Alcohol Self-Administration in Alcohol-Preferring Rats.
Srisontiyakul J; Kastman HE; Krstew EV; Govitrapong P; Lawrence AJ
Neurochem Res; 2016 Dec; 41(12):3206-3214. PubMed ID: 27573375
[TBL] [Abstract][Full Text] [Related]
11. AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology.
Cippitelli A; Wu J; Gaiolini KA; Mercatelli D; Schoch J; Gorman M; Ramirez A; Ciccocioppo R; Khroyan TV; Yasuda D; Zaveri NT; Pascual C; Xie XS; Toll L
Br J Pharmacol; 2015 Apr; 172(7):1834-45. PubMed ID: 25440006
[TBL] [Abstract][Full Text] [Related]
12. r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.
Beckmann JS; Meyer AC; Pivavarchyk M; Horton DB; Zheng G; Smith AM; Wooters TE; McIntosh JM; Crooks PA; Bardo MT; Dwoskin LP
Neurochem Res; 2015 Oct; 40(10):2121-30. PubMed ID: 26227997
[TBL] [Abstract][Full Text] [Related]
13. Nicotine Enhances the Hypnotic and Hypothermic Effects of Alcohol in the Mouse.
Slater CA; Jackson A; Muldoon PP; Dawson A; O'Brien M; Soll LG; Abdullah R; Carroll FI; Tapper AR; Miles MF; Banks ML; Bettinger JC; Damaj IM
Alcohol Clin Exp Res; 2016 Jan; 40(1):62-72. PubMed ID: 26727524
[TBL] [Abstract][Full Text] [Related]
14. The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
de Moura FB; McMahon LR
Psychopharmacology (Berl); 2017 Mar; 234(5):781-792. PubMed ID: 28028600
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
16. The nicotine + alcohol interoceptive drug state: contribution of the components and effects of varenicline in rats.
Randall PA; Cannady R; Besheer J
Psychopharmacology (Berl); 2016 Aug; 233(15-16):3061-74. PubMed ID: 27334469
[TBL] [Abstract][Full Text] [Related]
17. The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.
McCaul ME; Wand GS; Kuwabara H; Dannals RF; Wong D; Xu X
Nicotine Tob Res; 2020 May; 22(6):892-899. PubMed ID: 31096265
[TBL] [Abstract][Full Text] [Related]
18. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats.
Bito-Onon JJ; Simms JA; Chatterjee S; Holgate J; Bartlett SE
Addict Biol; 2011 Jul; 16(3):440-9. PubMed ID: 21392178
[TBL] [Abstract][Full Text] [Related]
19. Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.
Chatterjee S; Steensland P; Simms JA; Holgate J; Coe JW; Hurst RS; Shaffer CL; Lowe J; Rollema H; Bartlett SE
Neuropsychopharmacology; 2011 Feb; 36(3):603-15. PubMed ID: 21048701
[TBL] [Abstract][Full Text] [Related]
20. Promoting activity of (α4)
Wang J; Blasio A; Chapman HL; Doebelin C; Liaw V; Kuryatov A; Giovanetti SM; Lindstrom J; Lin L; Cameron MD; Kamenecka TM; Pomrenze MB; Messing RO
Neuropsychopharmacology; 2020 Jan; 45(2):301-308. PubMed ID: 31394567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
